The mycofactocin biosynthesis pathway is one of the most abundant of any RiPP system in the collection of bacterial genomes sequenced to date. However, its species distribution is heavily skewed towards the Actinomycetota, including Mycobacterium tuberculosis, which is the causative agent of tuberculosis and therefore the number one killer among bacterial pathogens of humans. The system is virtually absent from the normal human microbiome, although common in soil bacteria.
# The biosynthesis of mycofactocin from its precursor peptide MftA begins with decarboxylation of the C-terminal tyrosine residue by the radical SAM enzyme MftC, with help from the precursor-binding protein MftB.
# However, MftC appears next to perform a further modification to the MftA precursor peptide, an easily missed isomerization, by introducing a tyramine-valine cross-link, and consuming another S-adenosylmethionine in the process. The need for two modifications to MftA by MftC might explain the high degree of amino acid conservation in the last eight residues of MftA, as compared to the level of conservation seen for PqqA, precursor of PQQ.
# Next, the creatininase homolog MftE releases the C-terminal dipeptide, VY* (valine-tyrosine, where * indicates that the tyrosine was previously modified).
# Next, MftD converts the VY-derived dipeptide to premycofactocin, which has a biologically active redox center.
# And lastly, the glycosyltransferase MftF builds onto premycofactocin a variably sized, beta-1,4 linked oligomeric chain of glucose (i.e. cellulose), sometimes substituting derivatives such as 2-O-methylglucose.
Mycofactocin, therefore, is not a single compound, but instead a mixture of closely related electron carriers that differ in the nature of their attached oligosaccharides.